

**CORRIGENDUM**



**Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’**

[Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]

**D. J. Slamon<sup>1\*</sup>, P. Neven<sup>2</sup>, S. Chia<sup>3</sup>, G. Jerusalem<sup>4</sup>, M. De Laurentiis<sup>5</sup>, S. Im<sup>6</sup>, K. Petrakova<sup>7</sup>, G. Valeria Bianchi<sup>8</sup>, M. Martín<sup>9</sup>, A. Nusch<sup>10</sup>, G. S. Sonke<sup>11</sup>, L. De la Cruz-Merino<sup>12</sup>, J. T. Beck<sup>13</sup>, Y. Ji<sup>14</sup>, C. Wang<sup>15</sup>, U. Deore<sup>14</sup>, A. Chakravarty<sup>14</sup>, J. P. Zarate<sup>14</sup>, T. Taran<sup>15</sup> & P. A. Fasching<sup>16</sup>**

<sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, USA; <sup>2</sup>Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium; <sup>3</sup>British Columbia Cancer Agency, Vancouver, Canada; <sup>4</sup>CHU Liege and Liège University, Liège, Belgium; <sup>5</sup>Istituto Nazionale Tumori IRCCS ‘Fondazione G. Pascale’, Naples, Italy; <sup>6</sup>Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea; <sup>7</sup>Masaryk Memorial Cancer Institute, Brno, Czech Republic; <sup>8</sup>Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; <sup>9</sup>Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid, Spain; <sup>10</sup>Practice for Hematology and Internal Oncology, Velbert, Germany; <sup>11</sup>Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, The Netherlands; <sup>12</sup>Hospital Universitario Virgen Macarena, Seville, Spain; <sup>13</sup>Highlands Oncology Group, Fayetteville; <sup>14</sup>Novartis Pharmaceuticals Corporation, East Hanover, USA; <sup>15</sup>Novartis Pharma AG, Basel, Switzerland; <sup>16</sup>Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen, Erlangen, Germany

The authors regret that at the time the article was published, Supplementary Table S2 contained errors. This has now been corrected.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.annonc.2021.05.353>

\*Correspondence to: D. J. Slamon

E-mail: [dslamon@mednet.ucla.edu](mailto:dslamon@mednet.ucla.edu) (D. J. Slamon).

0923-7534/© 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).